zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2022 / Oneness and Microbio (Shanghai) signed an agreement with Cho Pharma to jointly develop glycosylation-based nucleic acid delivery technology.

Oneness and Microbio (Shanghai) signed an agreement with Cho Pharma to jointly develop glycosylation-based nucleic acid delivery technology.

2022-12-20

Published Date:2022-12-20

Original Link:https://www.onenessbio.com/en/news_detail191_1.htm

No 2 Date of announcement 2022/12/20 Time of announcement 17:16:40
Subject Oneness and Microbio (Shanghai) signed an agreement with Cho Pharma to jointly develop glycosylation-based nucleic acid delivery technology.
To which item it meets paragraph 53 Date of events 2022/12/20
Statement
  1. Date of occurrence of the event:2022/12/20
  2. Company name:ONENESS BIOTECH CO., LTD.
  3. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
  4. Reciprocal shareholding ratios:NA
  5. Cause of occurrence:
    (1) Small nucleic acid medicines (eg. siRNA) have become the focus of global new drug development, and drug delivery technology is the key to the development of nucleic acid medicines. At present, the only successful technology is a nature glycan molecule called N-acetylgalactosamine (GalNAc) that is capable to deliver the medicine to the liver effectively. GalNAc proves that glycan molecules can be used as a key carrier for nucleic acid delivery. In addition to the liver, delivery technologies to other organs are urgently needed.
    (2) Oneness and Microbio (Shanghai) will collaborate with Cho Pharma, a company specialized in molecular glycosylation and will focus on development of glycosylation-based nucleic acid delivery technology. It is aimed to develop globally competitive nucleic acid medicines that can target to specific organs and achieve precision therapy.
  6. Countermeasures:None
  7. Any other matters that need to be specified:None